Utama › Liposarcoma › Massachusetts
Kajian klinikal Liposarcoma di Massachusetts
7 kajian untuk Liposarcoma sedang mencari peserta di lokasi di Massachusetts.
Bandar di Massachusetts
Teks kajian rasmi (Bahasa Inggeris)
Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas
- Dana-Farber Cancer Institute, Boston
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 1 Okt 2026 · NCT06422806A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism
- Investigative Site, Boston
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 28 Sep 2026 · NCT06881992Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma
- Dana-Farber/Harvard Cancer Center, Boston
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 10 Sep 2026 · NCT04031677Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma
- Dana-Farber Cancer Institute, Boston
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 4 Sep 2026 · NCT05711615STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas
- Dana Farber Cancer Institute, Boston
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Ogo 2026 · NCT06975293NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
- Dana Farber Cancer Institute, Boston
Mengambil pesertaFasa 1/2
Sehingga umur 30 · Semua jantina · Dikemas kini 3 Ogo 2026 · NCT06239272Prospective Study Evaluating the Treatment Outcomes for Localised Recurrent, Resectable Retroperitoneal Liposarcoma
- Brigham and Women's Hospital, Boston
Mengambil pesertaKajian pemerhatian
Umur 18 ke atas · Semua jantina · Dikemas kini 15 Jul 2026 · NCT07377747Daripada ClinicalTrials.gov, data diperoleh pada 4 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.